Open AccessDifferential DNA methylation analysis of SUMF2, ADAMTS5, and PXDN provides novel insights into colorectal cancer prognosis prediction in Taiwan
Author(s) -
Jing-Quan Su,
Pin-Yu Lai,
Pei-Hsuan Hu,
Je-Ming Hu,
Pi-Kai Chang,
Chaoyang Chen,
Jia-Jheng Wu,
Yu-Jyun Lin,
ChienAn Sun,
Tsan Yang,
Chih-Hsiung Hsu,
HuaChing Lin,
YuChing Chou
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i8.825
Subject(s) - dna methylation , oncology , cpg site , colorectal cancer , medicine , methylation , hazard ratio , proportional hazards model , cancer , cancer research , confidence interval , biology , gene , genetics , gene expression
Patients with colorectal cancer (CRC) undergo surgery, as well as perioperative chemoradiation or adjuvant chemotherapy primarily based on the tumor-node- metastasis (TNM) cancer staging system. However, treatment responses and prognostic outcomes of patients within the same stage vary markedly. The potential use of novel biomarkers can improve prognostication and shared decision making before implementation into certain therapies.